AUDUBON, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will feature its ExcelsiusGPS® revolutionary robotic guidance and navigation system along with its latest advancements in expandable interbody technology at the North American Spine Society (NASS) Annual Meeting being held September 26-29, 2018 in Los Angeles, CA.
Globus Medical’s participation at NASS includes two in-booth presentations from surgeons currently using ExcelsiusGPS® that highlight the versatility of robotic guidance and navigation in both minimally invasive and complex deformity procedures. In addition to the presentations, meeting attendees have the opportunity to discuss advancements in robotic surgery and experience the company’s most recent product innovations.
“As leaders in the musculoskeletal device industry, we are committed to supporting the research, education, and development of medical advancements through robotic spine surgery,” said Chief Executive Officer Dave Demski. “We are proud to be a sponsor of NASS and are excited to showcase the strong utilization and clinical experience with our system just one year after launch.”
Globus welcomes NASS attendees to case presentations in Booth #1411.
Wednesday, September 26th, 3:15PM
Minimally Invasive Cases with ExcelsiusGPS®
Sabino D’Agostino, MD
Charleston Brain and Spine, Charleston, SC
Thursday, September 27th, 3:15PM
Complex and Deformity Cases with ExcelsiusGPS®
Themistocles Protopsaltis, MD
NYU Langone Health, New York, NY
About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the operations of Nemaris and retain key employees, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Howard Cohen, DDS. says
Globus has shown interest in my U.S> patent # 7,824,445 for an adjustable motion preservation corpectomy devices to meet the demands of restoring various sized spaces following the removal of the anterior body of a diseased vertebra along with the adjacent discs. Most often the devices are needed when kyphoplasty or vertebroplasty have failed in treating burst fractures of the spine due to trauma following an automobile accident. Drug eluting factors are included in the patent to enhance osseous integration as well as pain and antimicrobial and anti-tumor factors. The devices require only a 510K as they fall into the category of “humanitarian exemption” therefore not requiring PMA. Patent #s 7,282,063 and 6,719,796 are also being offered that provide for motion preservation following discectomy for use at several levels of the spine.. I can be reached at 917-846-3399. Thank you. Howard Cohen, DDS.
Howard Cohen, DDS. says
Globus has shown interest in my U.S> patent # 7,824,445 for an adjustable motion preservation corpectomy devices to meet the demands of restoring various sized spaces following the removal of the anterior body of a diseased vertebra along with the adjacent discs. Most often the devices are needed when kyphoplasty or vertebroplasty have failed in treating burst fractures of the spine due to trauma following an automobile accident. Drug eluting factors are included in the patent to enhance osseous integration as well as pain and antimicrobial and anti-tumor factors. The devices require only a 510K as they fall into the category of “humanitarian exemption” therefore not requiring PMA. Patent #s 7,282,063 and 6,719,796 are also being offered that provide for motion preservation following discectomy for use at several levels of the spine.. I can be reached at 917-846-3399. Thank you. Howard Cohen, DDS.
Howard Cohen, DDS. says
Howard Cohen, DDS. says
September 26, 2018 at 7:51 pm
Globus has shown interest in my U.S> patent # 7,824,445 for an adjustable motion preservation corpectomy devices to meet the demands of restoring various sized spaces following the removal of the anterior body of a diseased vertebra along with the adjacent discs. Most often the devices are needed when kyphoplasty or vertebroplasty have failed in treating burst fractures of the spine due to trauma following an automobile accident. Drug eluting factors are included in the patent to enhance osseous integration as well as pain and antimicrobial and anti-tumor factors. The devices require only a 510K as they fall into the category of “humanitarian exemption” therefore not requiring PMA. Patent #s 7,282,063 and 6,719,796 are also being offered that provide for motion preservation following discectomy for use at several levels of the spine.. I can be reached at 917-846-3399. Thank you. Howard Cohen, DDS